Back to homepage

Infectious disease

The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

Authors: Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi

The aim of this study was to observe the safety and efficacy of AZB as an addition to the complex treatment of patients hospitalized with COVID-19. This study is the first exploratory
use of AZB in patients with COVID-19.

More

The race to a COVID-19 vaccine: opportunities and challenges in development and distribution

Authors: Rodrigo M Burgos, Melissa E Badowski, Emily Drwiega, Samaneh Ghassemi, Nikki Griffith, Fischer Herald, Mikayla Johnson, Renata O Smith, Sarah M Michienzi

This article discusses the unprecedented toll of COVID-19 and how it jumpstarted the race towards potential COVID-19 vaccinations, which have been developed in less than a year. It discusses how this feat was accomplished, and how clinical development, manufacturing scale-up and distribution are occurring in parallel for the four COVID-19 vaccine front-runners. It also discusses the many challenges that still lie ahead.

More

Current treatment in COVID-19 disease: a rapid review

Authors: Miguel Rodriguez-Guerra, Preeti Jadhav, Timothy J Vittorio

This review aims to assess the efficacy and safety of available therapies for COVID-19 in light of current evidence. These treatment options are compared based on their impact on symptom management, inpatient length of stay, and overall morbidity and mortality.

More

Key policy and programmatic factors to improve influenza vaccination rates based on the experience from four high-performing countries

Authors: George Kassianos MD, Ashis Banerjee MD, Florence Baron-Papillon MD, Alan W Hampson MD, Janet E McElhaney MD, Allison McGeer MD, Thierry Rigoine de Fougerolles MSc, Mitch Rothholz MD, Holly Seale MD, Litjen J Tan MD, Angus Thomson PhD, Olivier Vitoux MSc

The aim of this analysis was to identify factors that have been instrumental in achieving a high influenza vaccine coverage rate (VCR) in the scope of four benchmark countries in order to provide an organised list of factors that could be used by countries with lower VCRs to help improve and strengthen their own VCRs.

More

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Authors: Rodolfo Sacco MD, PhD, Vincenzo Messina MD, Umberto Vespasiani Gentilucci MD, Luigi Elio Adinolfi MD, Antonio Ascione MD, Giorgio Barbarini MD, Angelo Barlattani MD, Giuseppe Cariti MD, Raffaele Cozzolongo MD, Basilio Fimiani MD, Ruggiero Francavilla MD, Caterina Furlan MD, Giovanni Garrucciu MD, Vincenzo Iovinella MD, Luca Rinaldi MD, Massimo Marignani MD, Paola Begini MD, Valeria Pace Palitti MD, Adriano M Pellicelli MD, Gaetano Scifo MD, Antonio Facciorusso MD, Luca Giacomelli PhD, Aashni Shah BSc, Gaetano Bertino MD, Serena Perazzo MD, Giampaolo Bresci MD, Antonio Izzi MD

The aim of this retrospective, multicenter, field-practice study was to investigate the therapeutic efficacy and safety of the oral combination of daclatasvir and sofosbuvir, with or without ribavirin, in a large unselected cohort of patients with chronic hepatitis C virus infection.

More